Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Contineum Therapeutics, Inc. Class A Common Stock (CTNM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: CTNM (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit -20.55% | Avg. Invested days 21 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 167.13M USD | Price to earnings Ratio - | 1Y Target Price 24.8 |
Price to earnings Ratio - | 1Y Target Price 24.8 | ||
Volume (30-day avg) 51685 | Beta - | 52 Weeks Range 5.92 - 22.00 | Updated Date 04/2/2025 |
52 Weeks Range 5.92 - 22.00 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.18 |
Earnings Date
Report Date 2025-03-07 | When - | Estimate -0.435 | Actual -0.56 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -18.54% | Return on Equity (TTM) -26.19% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -31370794 | Price to Sales(TTM) 11.15 |
Enterprise Value -31370794 | Price to Sales(TTM) 11.15 | ||
Enterprise Value to Revenue 8.25 | Enterprise Value to EBITDA 20.76 | Shares Outstanding 19142400 | Shares Floating 13299011 |
Shares Outstanding 19142400 | Shares Floating 13299011 | ||
Percent Insiders 6.94 | Percent Institutions 82.58 |
Analyst Ratings
Rating 4.5 | Target Price 28.67 | Buy 2 | Strong Buy 2 |
Buy 2 | Strong Buy 2 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Contineum Therapeutics, Inc. Class A Common Stock
Company Overview
History and Background
Contineum Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing novel therapies for unmet medical needs in neurology, immunology, and oncology. Founded in 2020 (spun out of Pipeline Therapeutics), they are pursuing clinical programs targeting multiple sclerosis and idiopathic pulmonary fibrosis.
Core Business Areas
- Neurology: Development of therapies targeting neurological disorders, primarily multiple sclerosis (MS). Their primary asset is PIPE-307, an oral selective lysophosphatidic acid 1 receptor (LPA1R) antagonist currently in Phase 2 trials for relapsing-remitting MS.
- Immunology & Fibrosis: Development of therapies for immunological and fibrotic diseases, specifically idiopathic pulmonary fibrosis (IPF) with PIPE-791.
Leadership and Structure
The leadership team is headed by Carmine Stengone, President and CEO. They have a board of directors comprising experienced biotech executives and venture capitalists. The company structure reflects a typical biotech, with departments focused on R&D, clinical development, and business operations.
Top Products and Market Share
Key Offerings
- PIPE-307: An oral selective LPA1R antagonist being developed for the treatment of relapsing-remitting MS. It is currently in Phase 2 trials. Market share is currently 0% as it is not yet approved. Competitors include existing MS therapies from companies like Biogen (BIIB), Novartis (NVS), and Roche (RHHBY).
- PIPE-791: A small molecule inhibitor of a novel target, being developed for idiopathic pulmonary fibrosis (IPF). It is currently in early clinical development. Market share is currently 0% as it is not yet approved. Competitors include approved IPF therapies from Boehringer Ingelheim and Roche (RHHBY).
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, long development timelines, and significant regulatory hurdles. Competition is intense, with many companies vying to develop innovative therapies for various diseases. The MS and IPF markets are substantial, but crowded with existing treatments and other emerging therapies.
Positioning
Contineum Therapeutics is positioned as a clinical-stage biopharmaceutical company focused on developing novel therapies in areas of high unmet need. Its competitive advantage lies in its novel targets and differentiated mechanisms of action, aiming for improved efficacy and safety profiles compared to existing treatments.
Total Addressable Market (TAM)
The global multiple sclerosis market is projected to reach $34.8 billion by 2030. The IPF market is projected to reach over $5 billion by 2029. Contineum's positioning is geared towards capturing a portion of these markets by offering potentially superior treatments.
Upturn SWOT Analysis
Strengths
- Novel drug targets (LPA1R and novel target for IPF)
- Differentiated mechanisms of action
- Experienced management team
- Strong intellectual property position
- Clinical-stage assets with promising early data
Weaknesses
- Reliance on successful clinical trial outcomes
- Limited financial resources compared to larger pharmaceutical companies
- Single pipeline risk (dependence on PIPE-307 and PIPE-791)
- Relatively young company
Opportunities
- Positive clinical trial results leading to regulatory approval
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline through internal discovery or acquisitions
- Potential for orphan drug designation and expedited regulatory pathways
Threats
- Clinical trial failures
- Regulatory hurdles and delays
- Competition from existing therapies and emerging treatments
- Patent challenges
- Economic downturn affecting funding for biotechnology companies
Competitors and Market Share
Key Competitors
- Biogen (BIIB)
- Novartis (NVS)
- Roche (RHHBY)
- Boehringer Ingelheim
Competitive Landscape
Contineum faces significant competition from established pharmaceutical companies with approved therapies for MS and IPF. Its competitive advantage lies in its novel targets and potentially improved efficacy/safety profiles, but it needs to demonstrate these advantages in clinical trials.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is measured by progress in clinical development and successful fundraising rounds.
Future Projections: Future growth is contingent on positive clinical trial results for PIPE-307 and PIPE-791, potential partnerships, and successful commercialization of approved products. Analyst estimates vary widely based on clinical trial probabilities of success.
Recent Initiatives: Recent initiatives include advancing PIPE-307 into Phase 2 clinical trials and PIPE-791 into Phase 1.
Summary
Contineum Therapeutics is a clinical-stage biopharmaceutical company with novel drug targets and potential in MS and IPF. Success depends on favorable clinical trial outcomes and securing partnerships. The company faces significant competition and financial risks inherent in biotech development, making near term speculation risky but potentially rewarding with positive results.
Similar Companies
ALNY
Alnylam Pharmaceuticals Inc
ALNY
Alnylam Pharmaceuticals Inc
BIIB
Biogen Inc
BIIB
Biogen Inc
NVS
Novartis AG ADR
NVS
Novartis AG ADR
VRM
Vroom Inc
VRM
Vroom Inc
Sources and Disclaimers
Data Sources:
- Contineum Therapeutics Investor Relations
- SEC Filings (10-K, 10-Q)
- Industry Reports
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on individual due diligence and consultation with a qualified financial advisor. Market share data is estimated and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Contineum Therapeutics, Inc. Class A Common Stock
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2024-04-05 | President, CEO & Director Mr. Carmine N. Stengone MBA, MS | ||
Sector Healthcare | Industry Biotechnology | Full time employees 41 | Website https://www.contineum-tx.com |
Full time employees 41 | Website https://www.contineum-tx.com | ||
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications with high unmet need in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis, progressive multiple sclerosis, and chronic pain. It also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor which is in Phase 2 clinical trial to treat depression and relapse remitting MS; and CTX-343, a peripherally restricted LPA1R antagonist which is a brain penetrant drug candidate. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.